143 related articles for article (PubMed ID: 35496975)
1. High Risk Acute Promyelocytic Leukemia - An Enigma for Hematologists: Optimizing Treatment with APML-4 Protocol.
Kapoor J; Mirgh SP; Agrawal N; Khushoo V; Tejwani N; Singh R; Mehta P; Bhurani D; Ahmed R
Indian J Hematol Blood Transfus; 2022 Apr; 38(2):394-402. PubMed ID: 35496975
[TBL] [Abstract][Full Text] [Related]
2. Role of Prophylactic Steroids in Differentiation Syndrome.
Sultana J; Dutta J; Mustarin S; Dey P; Roy A; Mamoon MY
Cureus; 2022 Sep; 14(9):e29531. PubMed ID: 36312659
[TBL] [Abstract][Full Text] [Related]
3. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
4. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
[TBL] [Abstract][Full Text] [Related]
5. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
6. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ; Bradstock K; Supple SG; Catalano A; Collins M; Hertzberg M; Browett P; Grigg A; Firkin F; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Blood; 2012 Aug; 120(8):1570-80; quiz 1752. PubMed ID: 22715121
[TBL] [Abstract][Full Text] [Related]
7. Treatment related acute promyelocytic leukemia (t-APML) in breast cancer survivor treated with anthracycline based chemotherapy: rare case report.
Madabhavi I; Modi G; Panchal H; Patel A; Anand A; Parikh S
Int J Hematol Oncol Stem Cell Res; 2015 Oct; 9(4):215-7. PubMed ID: 26865933
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
Chen L; Zhu HM; Li Y; Liu QF; Hu Y; Zhou JF; Jin J; Hu JD; Liu T; Wu DP; Chen JP; Lai YR; Wang JX; Li J; Li JY; Du X; Wang X; Yang MZ; Yan JS; Ouyang GF; Liu L; Hou M; Huang XJ; Yan XJ; Xu D; Li WM; Li DJ; Lou YJ; Wu ZJ; Niu T; Wang Y; Li XY; You JH; Zhao HJ; Chen Y; Shen Y; Chen QS; Chen Y; Li J; Wang BS; Zhao WL; Mi JQ; Wang KK; Hu J; Chen Z; Chen SJ; Li JM
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33495363
[TBL] [Abstract][Full Text] [Related]
9. Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial.
Zhang X; Liu L; Yao Y; Gong S; Wang M; Xi J; Chen L; Wei S; Zhang H; Zhao C; Wang H
Trials; 2020 Jan; 21(1):7. PubMed ID: 31898521
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Acute Promyelocytic Leukemia with Single Agent Arsenic Trioxide: Experience from a Tertiary Care Center in India.
Udupa K; Thomas J; Udupa CB; Binu VS; Sharan P
Indian J Hematol Blood Transfus; 2017 Mar; 33(1):45-48. PubMed ID: 28194055
[TBL] [Abstract][Full Text] [Related]
12. Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
Kennedy GA; Marlton P; Cobcroft R; Gill D
Br J Haematol; 2000 Dec; 111(4):1103-5. PubMed ID: 11167746
[TBL] [Abstract][Full Text] [Related]
13. Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARalpha acute promyelocytic leukemia (APML).
George B; Poonkuzhali B; Srivastava VM; Chandy M; Srivastava A
Ann Hematol; 2005 Jun; 84(6):406-8. PubMed ID: 15592671
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
Min GJ; Cho BS; Park SS; Park S; Jeon YW; Yahng SA; Shin SH; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ
Ann Hematol; 2020 May; 99(5):973-982. PubMed ID: 32270215
[TBL] [Abstract][Full Text] [Related]
15. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
Am J Hematol; 2002 Aug; 70(4):292-9. PubMed ID: 12210810
[TBL] [Abstract][Full Text] [Related]
18. An Outcome Analysis of Childhood Acute Promyelocytic Leukemia Treated with Atra and Arsenic Trioxide, and Limited Dose Anthracycline.
Jabbar N; Khayyam N; Arshad U; Maqsood S; Hamid SA; Mansoor N
Indian J Hematol Blood Transfus; 2021 Oct; 37(4):569-575. PubMed ID: 34744341
[TBL] [Abstract][Full Text] [Related]
19. Differentiation Syndrome, a Side Effect From the Therapy of Acute Promyelocytic Leukemia.
Reyhanoglu G; Hughes B; King KE; Cambridge R
Cureus; 2020 Dec; 12(12):e12042. PubMed ID: 33447473
[TBL] [Abstract][Full Text] [Related]
20. Acute promyelocytic leukaemia presenting as necrotising fasciitis of the perineum (Fournier gangrene).
Furtado VF; Batalini F; Staziaki PV; Prilutskiy A; Sloan JM
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
